Investor Presentaiton

Investor presentation Full year 2018 Continued single digit volume growth within the insulin segments globally Slide 52 Fast-acting insulin Segment volume Premix insulin Long-acting insulin NovoRapidⓇ market share Segment volume NovoMix® market share Segment volume TresibaⓇ share - LevemirⓇ share tMU CAGR¹ volume: 5.1% 100% tMU 200 MI penetration: 78.0% 200 CAGR¹ volume: 1.5% MI penetration: 44.5% 100% 200 tMU CAGR¹ volume: 6.0% 100% MI penetration2: 84.0% 80% 80% 80% 160 160 150 60% 60% 60% 120 120 100 40% 40% 40% 80 80 40 + 20% 40 20% 50 20% 0% 0% 0% Nov 2013 Nov 2018 Nov 2013 Nov 2018 Nov Nov 2013 2018 1 CAGR for 5-year period; 2 Includes new-generation insulin. tMU: Thousand mega units Note: Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology Source: IQVIA MAT Nov, 2018 volume figures changing diabetes novo nordisk

View entire presentation